Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip
The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...
Jim Cramer on Vertex Pharmaceuticals Incporated (VRTX): ‘This Is Hardly Down For The Year. I Think It Can Still Go Lower’
We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going ...
CNET13d
Kidney Health One Bite at a Time: Top 13 Foods That Will Safeguard Your Health
Omega-3 fats may help reduce fat levels (triglycerides) in the blood and may also lower blood pressure, according to the National Kidney Foundation. If you have CKD, you may need to keep an eye ...
Investing15d
Ultragenyx Pharmaceutical's SWOT analysis: rare disease biotech stock at crossroads
Ultragenyx is advancing several gene therapy candidates: DTX401 for Glycogen Storage Disease Type Ia (GSD1a): A Biologics License Application (BLA) filing is planned for mid-2025, with promising ...
Pharmaceutical Technology16d
Risk adjusted net present value: What is the current valuation of Vertex Pharmaceuticals’s Inaxaplin?
Inaxaplin is under development for the treatment of APO-L1 mediated kidney diseases including focal segmental glomerulosclerosis (FSGS). The drug candidate is administered through oral route. It acts ...
Wall Street Journal16d
Vertex Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Reuters16d
Europe allows Novo to include reduction of kidney disease in Ozempic label
HELSINKI, Dec 12 (Reuters) - The European Medicines Agency (EMA) will allow Novo Nordisk (NOVOb.CO), opens new tab to add risk reduction for events related to kidney disease to the label of its ...
Nature17d
Chronic kidney disease articles from across Nature Portfolio
Chronic kidney disease (CKD) is defined as a progressive loss of renal function that lasts for more than 3 months, and is classified according to the degree of kidney damage – measured by the le ...
BioSpace17d
Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million before fees ...
Morningstar17d
Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million before fees and expenses.
FierceBiotech18d
CervoMed's ex-Vertex drug fails to reduce dementia symptoms in phase 2 trial
Vertex had developed the candidate as a treatment for rheumatoid arthritis, taking it as far as a midphase trial in the setting. When EIP merged with Diffusion Pharmaceuticals last year to create ...